Riot Platforms, Inc. annual report, FY2014

Filing identity and reporting period

The supplied filing is Venaxis, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 30, 2015. It does not identify Riot Platforms, Inc.; the company and period in the request metadata do not match the filing text. This is an annual report, not a standalone fourth-quarter filing.

Business context and financial performance

Venaxis was developing and commercializing blood-based diagnostic products, principally APPY 1, a test intended to help identify patients at low risk for acute appendicitis. Its operations were focused on product development, regulatory clearance and early European commercialization.

Revenue comprised APPY 1 sales and amortized animal-health license revenue. Two European distributors accounted for all 2014 sales; one represented 89%. R&D expense declined 40% year over year to $4.03 million, largely after completion of APPY 1 U.S. pivotal-trial enrollment, while SG&A increased 19% to $6.56 million.

Balance sheet, liquidity and financing

At year-end 2014, cash and cash equivalents were $3.54 million and short-term investments were $21.00 million, for combined cash and liquid investments of $24.54 million. Working capital was $23.11 million; total assets were $28.72 million and stockholders’ equity was $23.69 million. Total liabilities were $5.04 million. Notes and other obligations totaled $2.31 million, including approximately $2.15 million in mortgage notes; the mortgage includes a balloon maturity five years after its May 2013 refinancing.

Financing activities provided $19.64 million in 2014, including net proceeds from public equity offerings and warrant exercises. Shares outstanding increased from 21.45 million at year-end 2013 to 30.99 million at year-end 2014. Management expected available working capital to cover estimated needs through the remainder of 2015 and into early 2016, while continuing to seek financing. The company reported recurring operating losses and negative operating cash flows.

Material developments, outlook and risks

• On January 27, 2015, the FDA informed Venaxis that APPY 1 did not meet criteria for clearance as a Class II device based on the de novo submission and amendment. The company was evaluating possible next steps, including a narrower indication, advancing APPY 2, or other regulatory or commercial paths. U.S. commercialization was suspended pending that assessment.
• APPY 1 had CE marking in Europe. Venaxis reported 2014 adult-sample results of 97.5% sensitivity, 98.4% negative predictive value and 36.5% specificity, and in February 2015 filed to expand its European indication to adults. European sales remained early and concentrated among a small number of distributors.
• Management anticipated lower 2015 R&D spending than in 2014, partly offset by APPY 2 development. It also identified further financing, cost control, partnering or licensing, and other strategic options as priorities. No quantified revenue or earnings guidance was provided.
• Key risks include failure to obtain U.S. regulatory clearance, inability to commercialize profitably or raise additional capital, continuing losses, distributor concentration, product adoption and reimbursement uncertainty, and potential impairment of patent-related assets.
• Legal matters include a Bealer contract-breach complaint and a securities class-action complaint filed in February 2015; Venaxis said it believed the allegations were without merit and intended to defend them. A prior securities case was dismissed, with the dismissal affirmed on appeal in October 2014.
• After year-end, the stock fell as low as $0.40 following the FDA decision; Nasdaq notified the company in March 2015 that it had failed the $1.00 minimum bid-price standard for 30 consecutive trading days. The filing says it had at least six months to regain compliance, with no assurance it would retain its listing.

Most important facts to verify

• Confirm the filing belongs to the intended issuer: the document is for Venaxis, Inc., not Riot Platforms, Inc.
• Review the FDA’s January 2015 decision and the company’s subsequent regulatory strategy; the filing does not establish a successful clearance pathway.
• Assess cash runway against operating cash use and financing needs, including whether additional capital was obtained after the filing.
• Verify subsequent European distributor sales, adult-indication status and customer concentration.
• Check the status and potential financial exposure of the Bealer and Boldt lawsuits, as well as Nasdaq bid-price compliance.
• Reconcile dilution from the 2014 equity offering, warrant exercises and outstanding options and warrants.